Raloxifene inhibits cloned Kv4.3 channels in an estrogen receptor-independent manner

详细信息    查看全文

• 作者：Yun Ju Chae ; Dae Hun Kim ; Hong Joon Lee…
• 关键词：Kv4.3 ; Raloxifene ; Estrogen receptor ; RT ; PCR
• 刊名：Pfl篓鹿gers Archiv - European Journal of Physiology
• 出版年：2015
• 出版时间：August 2015
• 年：2015
• 卷：467
• 期：8
• 页码：1663-1676
• 全文大小：1,244 KB
• 参考文献：1.Ahn HS, Choi JS, Choi BH, Kim MJ, Rhie DJ, Yoon SH, Jo YH, Kim MS, Sung KW, Hahn SJ (2005) Inhibition of the cloned delayed rectifier K+ channels, Kv1.5 and Kv3.1, by riluzole. Neuroscience 133:1007-9PubMed View Article
  2.Ahn HS, Kim SE, Jang HJ, Kim MJ, Rhie DJ, Yoon SH, Jo YH, Kim MS, Sung KW, Hahn SJ (2006) Interaction of riluzole with the closed inactivated state of Kv4.3 channels. J Pharmacol Exp Ther 319:323-1PubMed View Article
  3.Beck EJ, Bowlby M, An WF, Rhodes KJ, Covarrubias M (2002) Remodelling inactivation gating of Kv4 channels by KChIP1, a small-molecular-weight calcium-binding protein. J Physiol 538:691-06PubMed Central PubMed View Article
  4.Beck EJ, Covarrubias M (2001) Kv4 channels exhibit modulation of closed-state inactivation in inside-out patches. Biophys J 81:867-3PubMed Central PubMed View Article
  5.Bett GC, Morales MJ, Strauss HC, Rasmusson RL (2006) KChIP2b modulates the affinity and use-dependent block of Kv4.3 by nifedipine. Biochem Biophys Res Commun 340:1167-7PubMed View Article
  6.Birnbaum SG, Varga AW, Yuan LL, Anderson AE, Sweatt JD, Schrader LA (2004) Structure and function of Kv4-family transient potassium channels. Physiol Rev 84:803-3PubMed View Article
  7.Bryant HU, Glasebrook AL, Yang NN, Sato M (1999) An estrogen receptor basis for raloxifene action in bone. J Steroid Biochem Mol Biol 69:37-4PubMed View Article
  8.Butterworth JF, Strichartz GR (1990) Molecular mechanisms of local anesthesia: a review. Anesthesiology 72:711-4PubMed View Article
  9.Chung MT, Cheng PY, Lam KK, Chen SY, Ting YF, Yen MH, Lee YM (2010) Cardioprotective effects of long-term treatment with raloxifene, a selective estrogen receptor modulator, on myocardial ischemia/reperfusion injury in ovariectomized rats. Menopause 17:127-4PubMed View Article
  10.Delpon E, Valenzuela C, Gay P, Franqueza L, Snyders DJ, Tamargo J (1997) Block of human cardiac Kv1.5 channels by loratadine: voltage-, time- and use-dependent block at concentrations above therapeutic levels. Cardiovasc Res 35:341-0PubMed View Article
  11.Demo SD, Yellen G (1991) The inactivation gate of the Shaker K+ channel behaves like an open-channel blocker. Neuron 7:743-3PubMed View Article
  12.Dixon JE, Shi W, Wang HS, McDonald C, Yu H, Wymore RS, Cohen IS, McKinnon D (1996) Role of the Kv4.3 K+ channel in ventricular muscle. A molecular correlate for the transient outward current. Circ Res 79:659-8PubMed View Article
  13.Dodge JA, Lugar CW, Cho S, Short LL, Sato M, Yang NN, Spangle LA, Martin MJ, Phillips DL, Glasebrook AL, Osborne JJ, Frolik CA, Bryant HU (1997) Evaluation of the major metabolites of raloxifene as modulators of tissue selectivity. J Steroid Biochem Mol Biol 61:97-06PubMed View Article
  14.Eghbali M, Deva R, Alioua A, Minosyan TY, Ruan H, Wang Y, Toro L, Stefani E (2005) Molecular and functional signature of heart hypertrophy during pregnancy. Circ Res 96:1208-6PubMed View Article
  15.Eghbali M, Wang Y, Toro L, Stefani E (2006) Heart hypertrophy during pregnancy: a better functioning heart? Trends Cardiovasc Med 16:285-1PubMed View Article
  16.Feng J, Wang Z, Li GR, Nattel S (1997) Effects of class III antiarrhythmic drugs on transient outward and ultra-rapid delayed rectifier currents in human atrial myocytes. J Pharmacol Exp Ther 281:384-2PubMed
  17.Grammer JB, Bosch RF, Kuhlkamp V, Seipel L (2000) Molecular remodeling of Kv4.3 potassium channels in human atrial fibrillation. J Cardiovasc Electrophysiol 11:626-3PubMed View Article
  18.Heringa M (2003) Review on raloxifene: profile of a selective estrogen receptor modulator. Int J Clin Pharmacol Ther 41:331-5PubMed View Article
  19.James AF, Choisy SC, Hancox JC (2007) Recent advances in understanding sex differences in cardiac repolarization. Prog Biophys Mol Biol 94:265-19PubMed View Article
  20.Jeong I, Choi BH, Hahn SJ (2011) Rosiglitazone inhibits Kv4.3 potassium channels by open-channel block and acceleration of closed-state inactivation. Br J Pharmacol 163:510-0PubMed Central PubMed View Article
  21.Jeong EJ, Liu Y, Lin H, Hu M (2005) Species- and disposition model-dependent metabolism of raloxifene in gut and liver: role of UGT1A10. Drug Metab Dispos 33:785-4PubMed View Article
  22.Kaab S, Dixon J, Duc J, Ashen D, Nabauer M, Beuckelmann DJ, Steinbeck G, McKinnon D, Tomaselli GF (1998) Molecular basis of transient outward potassium current downregulation in human heart failure: a decrease in Kv4.3 mRNA correlates with a reduction in current density. Circulation 98:1383-3PubMed View Article
  23.Kemp DC, Fan PW, Stevens JC (2002) Characterization of raloxifene glucuronidation in vitro: contribution of intestinal metabolism to presystemic clearance. Drug Metab Dispos 30:694-00PubMed View Article
  24.Liew R, Stagg MA, MacLeod KT, Collins P (2004) Raloxifene acutely suppresses ventricular myocyte contractility through inhibition of the L-type calcium current. Br J Pharmacol 1
• 作者单位：Yun Ju Chae (1)
  Dae Hun Kim (2)
  Hong Joon Lee (3)
  Ki-Wug Sung (3)
  Oh-Joo Kwon (2)
  Sang June Hahn (1)
  
  1. Department of Physiology, College of Medicine, The Catholic University of Korea, 222 Banpo-daero, Seocho-gu, Seoul, 137-701, South Korea
  2. Department of Biochemistry, College of Medicine, The Catholic University of Korea, Seoul, 137-701, South Korea
  3. Department of Pharmacology, College of Medicine, The Catholic University of Korea, Seoul, 137-701, South Korea
  
• 刊物主题：Human Physiology;
• 出版者：Springer Berlin Heidelberg
• ISSN：1432-2013

文摘

Raloxifene is widely used for the treatment and prevention of postmenopausal osteoporosis. We examined the effects of raloxifene on the Kv4.3 currents expressed in Chinese hamster ovary (CHO) cells using the whole-cell patch-clamp technique and on the long-term modulation of Kv4.3 messenger RNA (mRNA) by real-time PCR analysis. Raloxifene decreased the Kv4.3 currents with an IC50 of 2.0?μM and accelerated the inactivation and activation kinetics in a concentration-dependent manner. The inhibitory effects of raloxifene on Kv4.3 were time-dependent: the association and dissociation rate constants for raloxifene were 9.5?μM??s? and 23.0?s?, respectively. The inhibition by raloxifene was voltage-dependent (δ--.13). Raloxifene shifted the steady-state inactivation curves in a hyperpolarizing direction and accelerated the closed-state inactivation of Kv4.3. Raloxifene slowed the time course of recovery from inactivation, thus producing a use-dependent inhibition of Kv4.3. β-Estradiol and tamoxifen had little effect on Kv4.3. A preincubation of ICI 182,780, an estrogen receptor antagonist, for 1?h had no effect on the inhibitory effect of raloxifene on Kv4.3. The metabolites of raloxifene, raloxifene-4-glucuronide and raloxifene-6-glucuronide, had little or no effect on Kv4.3. Coexpression of KChIP2 subunits did not alter the drug potency and steady-state inactivation of Kv4.3 channels. Long-term exposure to raloxifene (24?h) significantly decreased the expression level of Kv4.3 mRNA. This effect was not abolished by the coincubation with ICI 182,780. Raloxifene inhibited Kv4.3 channels by interacting with their open state during depolarization and with the closed state at subthreshold potentials. This effect was not mediated via an estrogen receptor.